Rabar S, Lau R, O'Flynn N, et al. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012;345:e3698.Rabar S, Lau R, O'Flynn N, Li L, Barry P. Risk assessment of fragility fractures: 33 summary of NICE guidance. BMJ 2012;345:e3698 doi: 34 10.1136/bmj.e3698...
Rabar S, Lau R, O'Flynn N, Li L, Barry P (2012) Risk assessment of fragility fractures: summary of NICE guidance. BMJ 345: e3698.Rabar S, Lau R, O'Flynn N et al. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012;345:e3698....
[4]. National Institute of Health and Care Excellence (NICE). Evidence review for statins: efficacy and adverse effects. NICE, London 2023.https://www.nice.org.uk/guidance/ng238/evidence/c-statins-efficacy-and-adverse-effects-pdf-13253901663. [5]. National Institute of Health and Care Excelle...
ardisease:riskassessmentandreduction,includinglipidmodificat ion,(2023-12)[2024-01-01].https://www.nice.org.uk/guidance/ng23 8/resources/cardiovascular-diseaserisk-assessment-and-reduction-inclu ding-lipid-modificationpdf-66143902851781. [5]Hippisley-CoxJ,CouplandC,BrindleP.Developmentandvalid ationof...
[4]. National Institute of Health and Care Excellence (NICE). Evidence review for statins: efficacy and adverse effects. NICE, London 2023.https://www.nice.org.uk/guidance/ng238/evidence/c-statins-efficacy-and-adverse-effects-pdf-13253901663. ...
[4]. National Institute of Health and Care Excellence (NICE). Evidence review for statins: efficacy and adverse effects. NICE, London 2023.https://www.nice.org.uk/guidance/ng238/evidence/c-statins-efficacy-and-adverse-effects-pdf...
Cardiovascular disease risk assessment and reduction: summary of updated NICE guidance. Samarasekera E J, Clark C E, Kaur S, Patel R S, Mills J. BMJ 2023; 381:p1028 doi:10.1136/bmj.p1028 医生须知要点: 管理心血管疾病(...
[4]. National Institute of Health and Care Excellence (NICE). Evidence review for statins: efficacy and adverse effects. NICE, London 2023.https://www.nice.org.uk/guidance/ng238/evidence/c-statins-efficacy-and-adverse-effects-pdf-13253901663. ...
.uk/guidance/ng238 ©NICE2023.Allrightsreserved.SubjecttoNoticeofrights(.uk/terms-and- conditions#notice-of-rights). Cardiovasculardisease:riskassessmentandreduction,includinglipidmodification (NG238) Yourresponsibility TherecommendationsinthisguidelinerepresenttheviewofNICE,arrivedataftercareful ...
Cardiovascular disease risk assessment and reduction: summary of updated NICE guidance. Samarasekera E J, Clark C E, Kaur S, Patel R S, Mills J. BMJ 2023; 381:p1028 doi:10.1136/bmj.p1028 管理心血管疾病(CVD)风险需采用个体化方法,其中改善生活方式是第一步医生须知要点: ...